Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
about
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsThe clinical application of linagliptin in AsiansAddition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysisDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonA systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapyEfficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trialsClinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series.Empagliflozin/linagliptin single-tablet combination: first-in-class treatment optionUse of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.Linagliptin: from bench to bedside.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.Implications of incretin-based therapies on cardiovascular disease.Pharmacologic treatment of type 2 diabetes: oral medications.Combination therapy when metformin is not an option for type 2 diabetes.Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
P2860
Q26749524-29F831FC-73A8-44A7-9453-113C10A8056AQ26781942-40C98602-400B-4E4F-92B5-EE1C6A4CB5B6Q28275281-744E6CF7-DCD2-4E5F-8107-4AF96B59C6AEQ28294225-B01653BE-ED25-4E47-9AE2-E23C94DE8939Q30240823-FDEAC4B4-B60D-4C12-9651-2EA955769D10Q33785197-0AEFC46B-7F36-4E63-8C99-9A9923EB44BCQ33859245-C0528643-5791-4E5C-BB7D-033A89124156Q34419202-F72B3C0A-E704-498A-91AE-DD7C47D3685FQ35236019-1066B01C-051A-4DF1-B17F-24C5E2196273Q36124544-4CBE72CF-84CD-41CD-9D8E-DA4543F007B5Q37015654-6DDFA8B3-7F9E-4FDA-9A45-AD56FF77FE99Q37308941-5A1F073D-ABA7-405E-AAAC-0ABF0B087FFEQ38058568-6615447D-C00D-4E47-889C-A54457B2F42FQ38113093-4E5F721F-CB52-4E68-B689-6BE38AA67E9FQ38213703-19704B8D-244A-42BE-ADC9-BA909E303E40Q38258278-5408CD6B-153D-474C-B841-76405F6B5DBCQ38263364-86C91892-3D11-46D8-A6A3-B293EC9B6960Q38264374-E43D4FDF-DF04-4C5A-9E67-7F6FE0BB3BF2Q38350347-3758E749-5D0A-43AA-8DF4-1BC2F748229BQ38377267-61653513-A764-4D92-9B71-4CC798AE0907Q38618835-03304B82-E969-4C45-AAA1-371C4777187DQ38795046-57B105A8-5E34-4F62-A279-5DE48BD4BF69Q39157526-AB7829E0-DCDB-4DC5-99B6-6DE430644278Q39855313-AEE4FE6C-E596-4889-A1DA-54879E293FCAQ40487459-F139B781-F1F7-4C5E-A830-8752A9552DEBQ41117483-8E99A0B4-13D8-4A79-85A9-9BC3285B38A1Q43462577-0DCE4C36-1159-4E50-93C8-C4863943B229Q44211603-08825F9D-CC3D-4A22-995F-1F197C33C956Q47173429-B6BAE658-83F2-4887-9CF2-E494B81A56E9Q51280718-492B44D0-7ACD-41EC-9792-F8448E447D93
P2860
Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and tolerability of l ...... ind, placebo-controlled trial.
@en
type
label
Efficacy and tolerability of l ...... ind, placebo-controlled trial.
@en
prefLabel
Efficacy and tolerability of l ...... ind, placebo-controlled trial.
@en
P2093
P921
P1476
Efficacy and tolerability of l ...... ind, placebo-controlled trial.
@en
P2093
Andrew J Lewin
Dacheng Liu
Hans-Juergen Woerle
Lisa Arvay
Maximilian von Eynatten
Sanjay Patel
P304
1909-19.e15
P356
10.1016/J.CLINTHERA.2012.07.008
P577
2012-08-29T00:00:00Z